Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Zuellig Pharma introduces Eli Lilly’s innovative obesity and diabetes medicine, Mounjaro in Thailand: Bangkok, Thailand Thursday, May 29, 2025, 11:00 Hrs [IST] Zuellig Pharma, a ...

Weight-loss drugs cannot be a short-term solution and GPs will need to engage with obesity management as the medicines are ...

FAT JABS have taken the nation’s waistline by storm – trimming inches and helping thousands shed weight, and fast. But it ...

BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounja ...

BANGKOK, THAILAND – Media OutReach Newswire – 27 May 2025 – Zuellig Pharma, a leading healthcare solutions company in Asia, ...

Locally produced versions of drugs like Semaglutide are helpful for patients with obesity and diabetes, but unprescribed use raises concerns ...

India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...

Pharma giant Eli Lilly’s weight loss drug Mounjaro is priced between Rs. 10,000- ₹15,000 in India making it inaccessible to a ...

Tirzepatide discontinuation was associated with reduced cardiometabolic benefits especially among patients with body weight regain.

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.